The aim of the project is to develop an innovative pegylated form of interferon IFNa5 used in the treatment of hepatitis C, currently not developed anywhere in the world. First, IFNa5 will be developed, followed by pegylated protein IFNa5. The meaning of the pegylated protein is that the pegylated form of the protein is much more stable, more effective in the treatment of some genetic types of the hepatitis C virus, from which it is possible to develop a form of prologent drug that is superior to the usual forms of the drug. During the project, it is planned to first acquire specific R & D equipment for pegylated protein excretion and characterisation only for knife reactions and pegylated proteins. Using this equipment and the R & D equipment available at Biotechpharma UAB Biotechpharma, the applied research planned in the project will be carried out. The expected result of the project is the development and testing of interferon IFNa5 pegilating technology under laboratory conditions, and the production of a small batch of interferon IFNa5 tested in laboratory conditions as a medicinal extension in a stable form. Pegylated IFNa5 can be commercialised as a product — e.g. for pre-clinical and clinical studies according to orders and for contract manufacturing. Thus, the results of the project can become a patent medicine (what would be a great achievement of the Lithuanian biotechnology sector), of course, only a service biopharmaceutical company, which acquired its intellectual property from Biotechnological Pharmaceutical Centre Biotechpharma UAB, could see it before the patented medicine, but such a possibility is quite realistic. Biotechpharma UAB Biotechpharma could provide services — pegylated development of IFNa5 to medicine and outsourcing services.